Background Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit associated with an increase in sebum secretion. Topical treatment with adapalene and benzoyl peroxide (BPO) is considered effective when used either as monotherapy or in fixed-dose combinations. However, the combination gel of 0.3% adapalene with 2.5% benzoyl peroxide (A0.3%+BPO2.5%) has not been evaluated in Indian patients with acne. This study aimed to evaluate the safety and efficacy of A0.3%+BPO2.5% gel in Indian patients with moderate-to-severe acne vulgaris. Methodology This was a 12-week prospective, multicenter, open-label, phase IV study conducted at six centers in India. Safety was assessed based on local tolerability (stinging or burning, erythema, dryness, and scaling) and any reported adverse events. Efficacy was evaluated based on reductions in the number of inflammatory and noninflammatory lesions, the Investigator's Global Assessment (IGA) scale, and the Global Assessment of Improvement (GAI) score. The patient-reported outcome was measured using the Subject Satisfaction Questionnaire. Results Of the 135 patients, 132 completed the study between December 24, 2021, and July 18, 2022 (93.9% had moderate acne; 6.1% had severe acne at baseline). The A0.3%+BPO2.5% gel was well tolerated. The reductions in the severity scores of erythema, scaling, and dryness from baseline to week 12 were 38.9%, 47.4%, and 76.5%, respectively. A targeted reduction of ≥50% in the number of inflammatory and noninflammatory lesions was achieved in 115 (87.1%) and 109 (82.6%) patients, respectively. Based on the investigator's responses to the IGA questionnaire at week 12, 28% and 40.9% of patients had clear and almost clear skin, respectively. Using the GAI scale, investigators reported that at 12 weeks from baseline, most patients presented with improvements in symptoms, such as erythema, scaling, and dryness, and none reported any worsening. Treatment satisfaction was rated as 91% by the patients. Conclusions The A0.3%+BPO2.5% gel effectively reduced the inflammatory and noninflammatory lesions and was found to be safe and well tolerated in Indians with moderate‑to‑severe acne vulgaris., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Clinical Trials Registry - India issued approval CTRI/2021/06/034069. All patients provided written informed consent. Below are the names and approval numbers of centers where the trial was carried out: Basaveshwara Medical College & Hospital (Karnataka), Banaras Hindu University (Uttar Pradesh), College of Medicine & JNM Hospital (West Bengal), Om Sai Onco-Surgery Multispecialty Centre (Maharashtra), Post Graduate Institute of Medical Science (Chandigarh), and Derma World Skin & Hair Clinic (New Delhi) with IRB numbers ECR/1218/Inst/KA/2019, ECR/526/Inst/UP/2014/RR-17, ECR/674/Inst/WB/2014/RR-17, ECR/1112/Inst/MH/2018, ECR/25/Inst/CH/2013/RR-16, and ECR/310/Indt/DL/2018, respectively. The study was conducted with the approval of CDSCO (following the provisions outlined in the Drugs and Cosmetics Acts and Rules). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: The funding for manuscript development was supported by Galderma. Financial relationships: Dyotona Sen declare(s) employment from Galderma. Sameer Jadhwar declare(s) employment from Galderma. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Batra et al.)